← Back to patent-cliff list
WD-890
Tier C — Watch / tradeWD-890
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TYK2
Indications (approved)：Plaque psoriasis, Systemic lupus erythematosus, Cutaneous lupus erythematosus, Psoriasis
Regional status
US
-
EU
-
China
Phase III
2026-03-18
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of WD-890?
Approved indications include: Plaque psoriasis, Systemic lupus erythematosus, Cutaneous lupus erythematosus, Psoriasis.
When does the WD-890 patent expire?
No public expiry year is available for WD-890 yet; this page updates once verified.
How do I get a quote for WD-890 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29